NASDAQ:NKTX

Nkarta Stock Forecast, Price & News

$25.03
-0.13 (-0.52 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$24.24
$25.41
50-Day Range
$23.94
$36.68
52-Week Range
$22.46
$79.16
Volume196,298 shs
Average Volume229,680 shs
Market Capitalization$821.56 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NKTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Nkarta and its competitors with MarketBeat's FREE daily newsletter.


Nkarta logo

About Nkarta

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was incorporated in 2015 and is based in South San Francisco, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.69 out of 5 stars

Medical Sector

330th out of 2,099 stocks

Pharmaceutical Preparations Industry

153rd out of 830 stocks

Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Nkarta (NASDAQ:NKTX) Frequently Asked Questions

Is Nkarta a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nkarta in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Nkarta stock.
View analyst ratings for Nkarta
or view top-rated stocks.

What stocks does MarketBeat like better than Nkarta?

Wall Street analysts have given Nkarta a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Nkarta wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Nkarta's next earnings date?

Nkarta is scheduled to release its next quarterly earnings announcement on Thursday, August 19th 2021.
View our earnings forecast for Nkarta
.

How were Nkarta's earnings last quarter?

Nkarta, Inc. (NASDAQ:NKTX) announced its earnings results on Thursday, May, 13th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.10.
View Nkarta's earnings history
.

What price target have analysts set for NKTX?

5 brokers have issued 1-year price targets for Nkarta's shares. Their forecasts range from $41.00 to $81.00. On average, they expect Nkarta's share price to reach $64.00 in the next twelve months. This suggests a possible upside of 155.7% from the stock's current price.
View analysts' price targets for Nkarta
or view top-rated stocks among Wall Street analysts.

Who are Nkarta's key executives?

Nkarta's management team includes the following people:
  • Mr. Paul J. Hastings, CEO, Pres & Director (Age 61, Pay $820.1k)
  • Dr. Nadir Mahmood Ph.D., Chief Financial & Bus. Officer (Age 42, Pay $479.18k)
  • Dr. Alicia J. Hager, Chief Legal Officer & Corp. Sec. (Age 51, Pay $420.63k)
  • Dr. Ralph Brandenberger Ph.D., Sr. VP of Technical Operations (Age 51)
  • Dr. James Trager Ph.D., Ph.D., Chief Scientific Officer (Age 57)
  • Dr. Kanya Rajangam, Chief Medical Officer (Age 47)

Who are some of Nkarta's key competitors?

What other stocks do shareholders of Nkarta own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nkarta investors own include Axcella Health (AXLA), Cronos Group (CRON), Square (SQ), Advanced Micro Devices (AMD), ASML (ASML), Beyond Meat (BYND), Citigroup (C), salesforce.com (CRM), CVS Health (CVS) and DraftKings (DKNG).

When did Nkarta IPO?

(NKTX) raised $150 million in an initial public offering (IPO) on Friday, July 10th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, Evercore ISI, Stifel and Mizuho Securities served as the underwriters for the IPO.

What is Nkarta's stock symbol?

Nkarta trades on the NASDAQ under the ticker symbol "NKTX."

Who are Nkarta's major shareholders?

Nkarta's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.38%), Logos Global Management LP (3.84%), Price T Rowe Associates Inc. MD (1.67%), Wasatch Advisors Inc. (1.58%), Rock Springs Capital Management LP (1.50%) and Hillhouse Capital Advisors LTD. (1.10%). Company insiders that own Nkarta stock include James E Flynn, James Trager, Nadir Mahmood, Paul J Hastings, Plc Glaxosmithkline and Ralph Brandenberger.
View institutional ownership trends for Nkarta
.

Which major investors are selling Nkarta stock?

NKTX stock was sold by a variety of institutional investors in the last quarter, including Logos Global Management LP, Hillhouse Capital Advisors LTD., Price T Rowe Associates Inc. MD, Goldman Sachs Group Inc., Rock Springs Capital Management LP, BlackRock Inc., Pura Vida Investments LLC, and TD Asset Management Inc.. Company insiders that have sold Nkarta company stock in the last year include James Trager, Nadir Mahmood, Paul J Hastings, and Ralph Brandenberger.
View insider buying and selling activity for Nkarta
or view top insider-selling stocks.

Which major investors are buying Nkarta stock?

NKTX stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Millennium Management LLC, Sectoral Asset Management Inc, Caas Capital Management LP, Sphera Funds Management LTD., Wasatch Advisors Inc., Morgan Stanley, and Citigroup Inc.. Company insiders that have bought Nkarta stock in the last two years include James E Flynn, and Plc Glaxosmithkline.
View insider buying and selling activity for Nkarta
or or view top insider-buying stocks.

How do I buy shares of Nkarta?

Shares of NKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nkarta's stock price today?

One share of NKTX stock can currently be purchased for approximately $25.03.

How much money does Nkarta make?

Nkarta has a market capitalization of $821.56 million and generates $120,000.00 in revenue each year. The company earns $-91,360,000.00 in net income (profit) each year or ($3.05) on an earnings per share basis.

How many employees does Nkarta have?

Nkarta employs 95 workers across the globe.

What is Nkarta's official website?

The official website for Nkarta is www.nkartatx.com.

Where are Nkarta's headquarters?

Nkarta is headquartered at 6000 SHORELINE COURT SUITE 102, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Nkarta?

Nkarta's mailing address is 6000 SHORELINE COURT SUITE 102, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-215-0385 or via email at [email protected]


This page was last updated on 6/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.